Paying more than 1,100 times forward earnings for a company whose flagship next-generation rocket has yet to clear the launchpad is either a leap of faith or a miscalculation — and the market has not yet decided which.
Rocket Lab (NASDAQ: RKLB), currently priced at $61.53, sits roughly 59% below its 52-week high of $151, yet analysts still assign a consensus price target of $93.10, implying upside of about 51%.
The stock’s volatility is striking: a beta of 3.176 means outsized swings are routine, and shares have already demonstrated that with a 15.94% gain over just the past week.
What grounds the bull case is not Neutron but the business already operating around it, which delivered third-quarter revenue of $267.83 million, a 72.7% year-over-year increase that cleared Wall Street’s $257.18 million consensus.
More telling than the quarterly beat is the order book, where a record backlog of $3.57 billion — up 52% from the prior quarter — signals customers are committing capital well before Neutron has proven itself.
Neutron has already attracted 16 reserved missions collectively worth more than $515 million, with several booked at a raised base price of $70 million per flight, reflecting genuine commercial demand for medium-lift capacity.
Government contracts add structural ballast, including an $816 million Space Development Agency prime contract and a $397 million Flatellite award that diversify revenue well beyond launch services alone.
CEO Peter Beck framed the company’s position bluntly: “There have been two commercial companies that have developed a vehicle, brought it to market, and scaled. That has been SpaceX and Rocket Lab.”
SpaceX’s own difficulties provide an instructive backdrop, as the company lost Super Heavy Booster 22 during Starship Flight 15, diverting it from a planned tower catch to an offshore Gulf of Mexico splashdown for reasons not yet publicly confirmed.
Ship 42 did reach orbit on that same flight and successfully deployed all 26 Starlink V3 satellites, underscoring that even partial success at this scale represents a significant technical achievement.
A successful Starship upper-stage tower catch, if completed, would advance SpaceX’s full-reusability timeline ahead of Neutron’s own first flight, sharpening the competitive clock for Rocket Lab.
Neutron’s schedule slipped to no earlier than 2027 following a stage 1 tank test failure, and cryogenic qualification remains an outstanding hurdle before any launch attempt can proceed.
Management has guided that adjusted EBITDA could turn positive within six months of a successful Neutron first flight, meaning the financial inflection point is directly gated on hardware performance.
On the cost side, GAAP earnings per share came in at -$0.12, missing the -$0.0665 consensus estimate, with the shortfall driven by debt extinguishment losses and expenses connected to the pending Iridium Communications (NASDAQ: IRDM) acquisition.
Non-GAAP gross margin also compressed, falling to 38.4% from 41.9% in the prior period, and heavy equity issuance pushed fourth-quarter weighted share count to approximately 681 million.
Analysts have responded with skepticism on the earnings trajectory, cutting 2027 EPS estimates four times against a single upward revision over the past 30 days, even as 18 of 22 covering analysts maintain Buy or Strong Buy ratings.
With $4.45 billion in cash on hand and roughly 32.9% of the backlog expected to convert within twelve months, the company has the financial runway to absorb Neutron’s development costs — but dilution remains an ongoing drag.
The stock is down 11.8% year to date against an S&P 500 gain of 10.62%, and with Neutron cryogenic qualification, the Iridium close, and Q4 revenue against a $270 million to $290 million guide all approaching, the next few months will test whether the premium embedded in RKLB’s share price is earned or premature.
